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Abstract
The intracellular oligomerization of a-synuclein is associated with Parkinson’s disease and appears to be an important target
for disease-modifying treatment. Yet, to date, there is no specific inhibitor for this aggregation process. Using unbiased
systematic peptide array analysis, we indentified molecular interaction domains within the b-synuclein polypeptide that
specifically binds a-synuclein. Adding such peptide fragments to a-synuclein significantly reduced both amyloid fibrils and
soluble oligomer formation in vitro. A retro-inverso analogue of the best peptide inhibitor was designed to develop the
identified molecular recognition module into a drug candidate. While this peptide shows indistinguishable activity as
compared to the native peptide, it is stable in mouse serum and penetrates a-synuclein over-expressing cells. The
interaction interface between the D-amino acid peptide and a-synuclein was mapped by Nuclear Magnetic Resonance
spectroscopy. Finally, administering the retro-inverso peptide to a Drosophila model expressing mutant A53T a-synuclein in
the nervous system, resulted in a significant recovery of the behavioral abnormalities of the treated flies and in a significant
reduction in a-synuclein accumulation in the brains of the flies. The engineered retro-inverso peptide can serve as a lead for
developing a novel class of therapeutic agents to treat Parkinson’s disease.
Citation: Shaltiel-Karyo R, Frenkel-Pinter M, Egoz-Matia N, Frydman-Marom A, Shalev DE, et al. (2010) Inhibiting a-Synuclein Oligomerization by Stable Cell-
Penetrating b-Synuclein Fragments Recovers Phenotype of Parkinson’s Disease Model Flies. PLoS ONE 5(11): e13863. doi:10.1371/journal.pone.0013863
Editor: Mark R. Cookson, National Institutes of Health, United States of America
Received May 4, 2010; Accepted October 15, 2010; Published November 10, 2010
Copyright:  2010 Shaltiel-Karyo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by funding from the Israeli Science Foundation (ISF) and the German-Israeli Project Cooperation (DIP) to UG. The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: vpr@tauex.tau.ac.il
Introduction
The role of protein oligomerization and deposition in
neurodegenerative diseases has become evident in diverse
disorders including Alzheimer’s disease (AD), Huntington’s
disease, Parkinson’s disease (PD), Creutzfeldt-Jacob disease, prion
disease, and type II diabetes [1–8]. In each case of these diseases, a
different endogenous protein self-assembles into highly ordered
fibrillar structures. Though there is no specific sequence homology
among these proteins, they are all thought to involve important
conformational changes in the corresponding protein, usually the
production of b-sheet structures which have a strong tendency to
aggregate into water-insoluble fibrous polymers [5,9]. It is
currently debated whether the precipitated insoluble fibrils or
actually soluble oligomers are the cytotoxic aggregative elements
that are associated with the pathologies of each of these diseases
[1,10–16]. Moreover, it is also not yet clear whether the soluble
oligomers are formed in an on-pathway fashion as intermediates
eventually leading to the non-soluble fibrils and plaques or formed
off- pathway by a separate mechanism.
PD, the second most common form of neurodegenerative
diseases after AD, is a devastating neurological disease without
cure, affecting 1–2% of the elderly population. It is characterize by
loss of neuromelanin-containing dopaminergic neurons in the
substantia nigra pars compacta with presence of eosinophillic,
intracytoplamic, proteinaceous inclusions termed Lewy bodies
(LB) and dystrophic Lewy neuritis (LN) in surviving neurons.
Among the clinical features of PD are motor impairments
involving resting tremor, bradykinesia, postural instability and
rigidity along with non-motoric symptoms such as autonomic,
cognitive and psychiatric problems. The cause of these patholog-
ical characteristics is not yet fully understood but it is believed that
environmental factors as well as a genetic causation or a
combination of the two might result in the abovementioned
clinical syndromes [17]. It is now known that less than 10% of the
PD cases have a strict familial etiology while the majority of cases
are sporadic [18]. Among the mutations associated with familial
PD, three missense mutations in the a-synuclein (a-syn) gene
termed A53T, A30P and E46K have been widely characterized
[19,20].
The 140 amino acid a-syn protein is a small, highly charged,
natively unfolded protein, first identified in 1977 as the major
component of LB and LN [21,22]. This was followed by the
discovery of the point mutations in its gene [23]. Besides its role in
PD, the protein is associated with pathological inclusions of several
other neurodegenerative diseases including dementia associated
with Lewy bodies, LB variant of AD, and multiple system atrophy
[24]. Three major regions are recognized in a-syn: the amino
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KTKEGV sequence, a hydrophobic central domain called the
non-amyloid component (NAC) region, and the carboxy terminal
region characterized by its highly negatively charged amino acids
[25,26]. The a-syn protein is predominantly expressed in neurons
of the central nervous system (CNS), where it is localized at pre-
synaptic termini in close proximity to synaptic vesicles, and can
associate with lipid membranes by forming amphipathic a-helices
[24].
a-syn is a member of the family of synuclein proteins, along with
b-synuclein (b-syn) and c-synuclein (c-syn) [27]. a-syn and b-syn
are found primarily in brain tissues located mainly in the pre-
synaptic nerve terminals, while c-syn is found primarily in the
peripheral nervous system and the retina, although it has also been
observed to be highly expressed in some tumor tissues, including
breast, ovarian and bladder tissues [24].
The sequence of the three synuclein protein is highly conserved,
especially within their N terminal domains. When the sequences of
a-syn and b-syn are compared, a major difference within the
hydrophobic central domain is apparent: b-syn, a 134 amino acid
protein, lacks the NAC region of a-syn and, in contrast to the
latter, does not aggregate to form amyloid fibrils under various
stress conditions such as free radicals or increased concentration
[9,28]. Moreover, b-syn was shown to inhibit the aggregation of a-
syn in vitro in a dose-dependent manner [29,30]. Uversky et al.
proposed that this inhibition occurs due to the incorporation of b-
syn into oligomeric intermediates which in turn leads to their
stabilization. It is hypothesized that b-syn interacts with a putative
transient oligomeric intermediate of a-syn, normally on its way to
form fibrils, resulting in the stabilization of the a-syn intermediate
and blocking its conversion into fibrils [31].
Based on the finding that b-syn inhibits the aggregation of a-
syn, Windisch and colleagues further examined the inhibitory
potential of several deletion mutants of b-syn, focusing on the N-
terminal 1–15 amino acids of the protein. The researchers
generated a peptide library containing different variations of
amino acid composition derived from this specific sequence of b-
syn, with the aim of finding a peptide that could be used for
therapeutic applications, or could serve as a basis for developing
peptidomimetic small molecules [32].
In the present work, we systematically mapped the entire
sequence of b-syn in order to identify other domains that have the
potential to facilitate the molecular recognition between b-syn and
a-syn. Based on these findings, we rationally designed modified
metabolically-stable peptides and analyzed their interaction with
a-syn using chemical and biophysical methods. These peptides
could be internalized into cultured cells and caused a marked
amelioration of the behavioral impairments in a PD fly model.
Methods
Peptide array
The molecular mapping of b-syn fragments binding a-syn was
performed using peptide array technology. Decamer peptides
corresponding to overlapping sequences of the full length, 134
amino acids, b-syn protein were synthesized on a cellulose
membrane matrix (JPT Peptide Technologies GmbH, Germany).
The first 15 amino acids were synthesized with 9 amino acids
overlap with a shift of one amino acid from one peptide to its
subsequent. The importance of this region was suggested
previously as a binding domain [32]. The rest of the peptide
was synthesized with five amino acids overlap. The peptides were
covalently bound to a Whatman 50 cellulose support via the C-
terminal amino acid residues. Two spots on the membrane
contained libraries of non-relevant peptides. These libraries were
supplied and synthesized by JPT company and were used as a
negative control.
After blocking, the membrane was incubated in the presence of
N-terminal histidine-tagged recombinant a-syn, followed by
treatment with HRP-conjugated anti-His monoclonal antibody.
In order to identify the strongest binding sites, an additional
membrane containing b-syn decamer peptides with a 9 amino acid
overlap between each sequential peptide along the protein was
used under more stringent conditions; this time we used a smaller
amount of a-syn reacting with the membrane and half the
concentration of the secondary antibody. Once b-syn binding sites
were identified, small b-syn derived peptides were synthesized.
Expression and purification of a-syn
The protein was expressed in pT7-7 BL21 E. coli bacteria. For
over expression, bacterial cultures were grown to logarithmic
stage in the presence of ampicillin (100 mg/l) and protein
expression was induced using IPTG (1 mM) for 3 hours. The
bacterial pellet was re-suspended in TEN buffer (50 mM Tris
pH 8.0, 10 mM EDTA, 150 mM NaCl), and frozen at 280uC
until purification.
Protein purification was accomplished using a non-chromato-
graphic method as described by Volles and Lansbury [33]. Briefly,
after boiling and centrifugation of the bacterial pellet, the
supernatant was removed to a fresh tube and streptomycin sulfate
(136 ml of a 10% solution/ml supernatant) and acetic acid (glacial,
228 ml/ml supernatant) were added, followed by additional
centrifugation for two minutes. The supernatant was removed
again and then precipitated with ammonium sulfate (saturated
ammonium sulfate at 4uC was used 1:1 v:v with supernatant). The
precipitated protein was collected by centrifugation, and the pellet
was washed once with 1 ml of 50% ammonium sulfate solution
(4uC; 1:1 v:v saturated ammonium sulfate (4uC):water). The
washed pellet was re-suspended in 900 ml of 100 mM ammonium
acetate (to form a cloudy solution) and precipitated by adding an
equal volume of 100% ethanol at room temperature. Ethanol
precipitation was repeated once more, followed by a final re-
suspension in 100 mM ammonium acetate, overnight dialysis to
water at 4uC, freezing in liquid nitrogen, and lyophilization.
For validation, the a-syn protein was later purified by an
additional method using chromatography and was tested for
aggregation inhibition using the same peptides. Briefly, the
bacterial pellet was re-suspended in 50 mM Tris, 50 mM KCl,
5 mM MgAc, 0.1% NaN3, pH 8.5 and was supplemented with
300 mM PMSF inhibitors. The solution was sonicated and
ultracentrifuged for 30 minutes at 14,000 RPM at 4uC. The
resulting supernatant was boiled for 15 minutes in a water bath.
To separate the precipitated proteins from the solution, the sample
was centrifuged for 20 minutes (7,000 RPM at 4uC). The
supernatant was filtered through a 0.45 mm filter and was kept
at 4uC for further purification.
The filtrated supernatant was applied on a HiPrep 16/10 QFF
anion exchange column. At 20 mM Tris, pH 8, a-syn has a net
negative charge, and can therefore interact with the positively
charged moieties (NH
+) of the column. The protein was eluted
using 30–40% of 20 mM Tris and 1 M NaCl solution (pH 8) and
was subjected to a HiLoad 26/20 superdex 200 size exclusion
column. Anion exchange fractions were loaded with 50 mM Tris/
HCl and 150 mM NaCl buffer (pH 7.5), and the monomer
fraction was analyzed by SDS-PAGE and was collected, dialyzed
overnight to ddH2Oa t4 uC, frozen in liquid nitrogen, and
lyophilized.
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a-syn was dissolved to a concentration of 200 mMi n1 0 0m M
Tris buffer (pH 7.4). In order to obtain the monomeric fraction, the
protein was filtered through a 100 kDa centricon. Since a-syn is not
a globular but rather a natively unfolded protein, only monomers
and some dimers pass through the membrane. The monomeric
protein was immediately mixed with or without different b-syn-
derived peptides at a 1:1 ratio to a final concentration of 100 mM.
The samples were incubated at 37uC with agitation of 850 RPM as
described by Tsigelny, et al. [34] and the rate of fibrillogenesis was
monitored using the thioflavin T (ThT) fluorescence assay
(excitation at 450 nm, 2.5 nm slit, and emission at 480 nm, 5 nm
slit), after three days of incubation. ThT was added to a 500-fold
diluted sample and fluorescence was measured using a Jobin Yvon
Horiba Fluoromax 3 fluorometer. To assure that b-syn-derived
peptidesdon’taggregate,theirfluorescencewasmeasuredascontrol
and subtracted from the test samples.
Transmission electron microscopy
Samples (10 ml) from the a-syn ThT fluorescence assay (with
and without inhibitors) were placed on 400-mesh copper grids
covered by carbon-stabilized Formvar film (SPI Supplies, West
Chester, PA). After 1.5 minutes, excess fluid was removed, and the
grids were negatively stained with 10 ml of 2% uranyl acetate
solution for two minutes. Finally, excess fluid was removed and the
samples were viewed by a JEOL 1200EX electron microscope
operating at 80 kV.
Determination of soluble oligomer formation
Monomeric a-syn was dissolved to a concentration of 200 mM
in 100 mM Tris buffer (pH 7.4) and was immediately mixed with
or without different b-syn-derived peptides at a 1:1 ratio to a final
concentration of 100 mM, as was described above for the ThT
fluorescence assay. After the samples were agitated at 37uC for
several days, 10 ml of the protein were centrifuged at 13,000 RPM
for 10 minutes, the supernatant was collected and was electro-
phoresed in acrylamide gel using native loading buffer without b-
mercaptoethanol or boiling. The gel was washed three times in
ddH2O and samples were transferred to the nitrocellulose
membrane using a semi-dry blot technique, applying 323 mA
current for 30 minutes. The membrane was blocked for one hour
using 5% milk diluted in TBS (0.3% Tween) while shaking. Anti a-
syn antibody, diluted 1:1,000 (Santa Cruz Biotechnology) in 5%
milk in TBS (0.3% Tween), was added to the membrane for two
hours of incubation followed by several washes with TBS (0.3%
Tween). Rabbit anti-mouse IgG (Fc specific)-HRP-conjugated
antibody diluted 1:5,000 in 5% milk diluted in TBS (0.3% Tween)
was added for one hour at room temperature while shaking. Blots
were developed after thorough TBS (0.3% Tween) washes, using
an Enhanced Chemiluminescence System (ECL) according to the
manufacturer’s manual.
NMR analysis
Peptide samples were prepared from peptides stored in
lyophilized form, dissolved in a solution containing 10%
deuterium oxide in 20 mM phosphate buffer and 50 mM NaCl
in ddH2O. Samples of peptides complexed with a-syn were
prepared from stock solutions of a-syn in 20 mM phosphate
solution to which NaCl and deuterium oxide were added to
achieve the above-mentioned concentrations, and the lyophilized
peptide was added at the designated molar ratio. pH was
measured for all samples. Samples were prepared in Shigemi
tubes with a final volume of 260 ml.
The NMR experiments were performed on a Bruker Avance
600 MHz DMX spectrometer operating at the proton frequency
of 600.13 MHz using a 5 mm selective probe equipped with a self-
shielded xyz-gradient coil. The transmitter frequency was set on
the HDO signal, which was calibrated according to temperature
(4uC–4.974 ppm; 10uC–4.821 ppm; 15uC–4.773 ppm; 37uC–
4.658 ppm). TOSCY [35,36] and NOESY [36,37] experiments
were acquired for each temperature and sample set.
Spectra were processed and analyzed with TOPSPIN software
(Bruker Analytische Messtechnik GmbH). Zero filling in the
indirect dimension, and data apodization with a shifted squared
sine bell window functions in both dimensions, were applied prior
to Fourier transformation for optimal resolution. The baseline was
further corrected in the direct dimension with a quadratic
polynomial function.
Resonance assignment was done according to the sequential
assignment methodology developed by Wu ¨thrich [John Wiley &
Sons, 38] based on the TOCSY and NOESY spectra measured
under identical experimental conditions. Chemical shift deviations
of the HN-Ha peaks were read from carefully calibrated, highly
resolved, strongly apodized overlaid 2D spectra.
In vitro assay of peptide stability
Peptides were dissolved to give a 1 mM solution in 50 mM Tris
buffer (pH 7.6). 120 ml of the peptide solution was diluted into a
10% freshly-made homogenate of mouse brain excluding the
cerebellum (in 16Tris buffer and 0.5% Triton X-100). A mixture
containing 20% peptide solution and 80% mouse brain homog-
enate was incubated at 37uC with delicate shaking for two hours.
The enzyme reaction was stopped by adding 0.1 M HCl solution,
followed by denaturation of the protein using methanol and
incubation at 20uC for one hour. The precipitated proteins were
centrifuged at 29,0006g for 20 minutes at 4uC and the
supernatant containing the peptide was concentrated under
vacuum and separated using a C18 HPLC column. The area of
the peak (UV absorbance at 280 nm) corresponding to the intact
peptide was compared with an equivalent sample incubated in
50 mM Tris buffer.
Cell line
SH-SY5Y cells (kindly provided by Prof. Daniel Offen, Tel Aviv
University), stably transfected with wild type a-syn, were
maintained with DMEM: F12 1:1 containing 5% fetal bovine
serum, 2 mM L-glutamine, 1000 U/ml penicillin-G sodium,
1 mg/ml streptomycin sulfate and 1 mM sodium pyruvate under
selective conditions with 100 mM G-418 at 37uC with 5% CO2.
Cells underwent differentiation with 10 mM retinoic acid (Sigma)
in complete growth medium, replaced every two days for a period
of eight days.
Peptide internalization into SH-SY5Y cells
The retro-inverso b-syn 36 peptide internalization into SH-
SY5Y cells was visualized by immunocytochemistry staining. 10
4
cells were seeded on a cover slip coated with poly-L-lysine (0.1%)
in a 24-well plate and underwent differentiation as described.
Differentiated cells were incubated with the peptide in the cells
growth medium for 30 minutes to 4 hours at 37uC. Cells were
washed with PBS and fixed with 4% paraformaldehyde in PBS for
30 minutes at room temperature and then washed twice with PBS
and permeabilized with 0.1% Triton in PBS for 2 minutes.
Following two PBS washes, cells were blocked with 10% normal
goat serum in 3% BSA for 30 minutes and incubated with anti a-
syn antibody (Santa Cruz Biotechnology) diluted 1:1000 and
Phalloidin 4 mg/ml (Sigma) for one hour, followed by an
b-Syn Fragments Inhibit PD
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rabbit IgG (Jackson ImmunoResearch). After being thoroughly
washed with PBS, cells were mounted using ProLong Antifade
(Invitrogene). Images were taken with LSM510 confocal micro-
scope (Zeiss).
Fly keeping
Flies were reared on standard cornmeal-molasses medium and
were kept at 25uC. As Drosophila females can store sperm cells in
their bodies, crosses were conducted using virgin females collected
no longer than eight hours after eclosion at 25uC or 18 hours after
eclosion at 18uC. The crosses were performed at 29uC. Adult
offspring (F1) from the crosses were collected up to 9 days after the
beginning of their eclosion at 25uC in order to avoid offspring
from the next generation (F2).
Fly crossing
Male flies carrying the driver elav
c155-Gal4 on their X
chromosome were crossed to females carrying the UAS-regulated
A53T a-syn transgene located on their X chromosome (kindly
provided by Prof. Mel Feany, Harvard Medical School). This
resulted in first generation (F1) female offspring expressing A53T a-
syn in their nervous system which served as our PD fly model. In
parallel, male flies carrying the driver elav
c155-Gal4 on their X
chromosome were crossed to wild type (Oregon-R) females and the
resultant F1, carrying only the elav
c155-Gal4 driver served as control
Figure 1. Mapping of the interaction areas between b-syn and a-syn. (A) Schematic illustration of interactions between b-syn and a-syn; a-
syn monomers (red) aggregate to form fibrils and oligomers. (B) b-syn (grey-blue) is known to inhibit the aggregation of a-syn. (C). Potential b-syn-
derived peptides (blue) as inhibitors of a-syn aggregation. (D) Molecular mapping of b-syn sequences that bind a-syn using peptide-array analysis. (E)
Screen for a-syn binding sequences within the b-syn protein. Decamer peptides corresponding to consecutive 9 residue overlapping sequences
whithin the first 15 amino acids of b-syn and 5 residue overlapping sequences of the rest of the protein were synthesized on a cellulose membrane
and incubated with His-labeled a-syn. (F) An additional screen was performed using more stringent conditions and a 9 residue overlapping along the
entire protein.
doi:10.1371/journal.pone.0013863.g001
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The retro-inverso b-syn 36 peptide was added to standard
cornmeal-molasses medium, upon cooking, at a concentration of
0.75 mg/ml. The peptide was mixed thoroughly into the medium
when it was at 40uC and the mixture was aliquoted into fly rearing
vials. The vials were kept at 4uC until use. Crosses were performed
either on regular Drosophila medium (control) or on medium
supplemented with the peptide. Animals fed on the appropriate
medium from the beginning of the larval stage. After eclosion,
adult offspring were transferred into a fresh vial containing regular
Drosophila medium on top of which a solution of 0.75 mg/ml
peptide was dripped every other day.
Locomotive (climbing) assay
Vials of each of the following four F1 classes: 1) Females
expressing A53T a-syn reared on regular medium; 2) Females
expressing A53T a-syn reared on medium supplemented with the
tested compound; 3) Control females carrying only the elav
c155-
Gal4 driver, reared on regular medium; 4) Control females
carrying only the elav
c155-Gal4 driver, reared on medium
supplemented with the tested compound, each containing 10 flies
were tapped gently on the table and were let to stand for 20
seconds. The percentage of flies which climbed along the test tube
was monitored over time. Each class had four independent vial
repeats.
Statistical analysis
P-values were calculated for comparison of female flies
expressing A53T a-syn reared on regular medium with female
flies expressing A53T a-syn on medium supplemented with the
tested compound and with control flies using one tail ANOVA test
with a value of 0.05. P,0.05 was considered significant.
Immuno-staining of adult fly brains
Fourteen-day old adult flies were dissected and their brains were
removed. After incubation in Paraformaldehyde the whole brains
were transferred to formic acid and blocked with 0.5% Triton in
5% BSA. Following an overnight incubation with anti a-syn
antibody (Santa Cruz Biotechnology) diluted 1:200, the brains
were stained with Cy5-conjugated goat anti-rabbit IgG (Jackson
ImmunoResearch). After being thoroughly washed with PBS, cells
were mounted using ProLong Antifade (Invitrogene). Images were
taken with LSM510 confocal microscope (Zeiss).
Results
Identification of the recognition domains between b-syn
and a-syn
The full length b-syn has been shown to inhibit the aggregation
of a-syn in a dose-dependent manner. Therefore the recognition
modules within the b-syn protein were systematically mapped
(illustrated in Figure 1A–D).
An overlapping peptide array technique was used for fine
molecular mapping using 9 amino acids overlapping decamer
peptides for the first 15 amino acids of the protein and 5 amino
acids overlapping decamer peptides for the rest of the protein
(Figure 1E). For validation, an additional set of decamer peptides
overlapping in 9 amino acids were synthesized on a membrane
and their binding detection to a-syn was performed under more
stringent conditions. A few binding regions were detected in the
first screen but only some of them appeared under more stringent
binding conditions (Figure 1F). These results lead to the synthesis
of seven candidate decamers for further analysis. These peptides
were termed b-syn 6, 14, 36, 37, 38, 39, 77, and 78 according to
the location of their first amino acid (Table 1). A septamer,
containing amino acids 9–15 termed b-syn 6short (Table 1), that
was shown to display significant inhibition of a-syn aggregation
[32] was used as positive control.
The peptides containing amino acids 36–39 of b-syn were of
special interest due to the presence of tyrosine. We and others have
previously identified an important role of aromatic amino acids in
the acceleration of amyloid fibrils formation [5,6,9,39,40].
Therefore, the presence of tyrosine within these peptides might
be useful in the inhibition of the self-assembly of a-syn.
Inhibition of formation of a-syn amyloid fibrils by b-syn-
derived peptides
Thioflavin-T (ThT) binding assay was used to examine and
quantify the inhibitory effect of the b-syn peptides on a-syn fibril
Table 1. b-syn derived peptides.
Peptide name Sequence Position within b-syn protein sequence
b-syn 6short (control) SMAKEGV 9–15
b-syn 14 GVVAAAEKTK 14–23
b-syn 36 GVLYVGSKTR 36–45
b-syn 37 VLYVGSKTRE 37–46
b-syn 38 LYVGSKTREG 38–47
b-syn 39 YVGSKTREGV 39–48
b-syn 77 AAATGLVKRE 77–86
b-syn 78 AATGLVKREE 78–87
b-syn 36 modifications (all aa are D enantiomers)
b-syn 36D GVLYVGSKTR 36–45
Retro inverso b-syn 36 RTKSGVYLVG 36–45
Acetylated and amidated retro inverso b-syn 36 Acetyl-RTKSGVYLVG-amide 36–45
b-syn 36D short YVGSKTR 39–45
Y39W b-syn 36D GVLWVGSKTR 36–45
doi:10.1371/journal.pone.0013863.t001
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amyloid fibril growth. a-syn was incubated for several days at
37uC with vigorous shaking to allow the formation of amyloid fibrils
with or without the different b-syn-derived peptides. The fibrilliza-
tion process was monitored for three days. Figure 2A demonstrates
that the formation of amyloid fibrils was significantly reduced in the
presence of several of the peptide inhibitors. A kinetic analysis was
performed for the two potential inhibitors b-syn 36 and b-syn 39
Figure 2. In vitro analysis of a-syn aggregation. (A) In vitro inhibition of a-syn fibrillar assembly. b-syn peptides were screened for inhibiting a-
syn aggregation using ThT (molar ratio 20:1 respectively). (B) Kinetic analysis of the aggregation of a-syn in the presence of b-syn peptides 36 and 39.
Control a-syn (¤), peptide b-syn 39 with a-syn (m), peptide b-syn 36 with a-syn (&). (C) Dose dependent inhibition effect of peptide b-syn 36 on a-
syn aggregation. (D-K) TEM images of a-syn fibrils with several peptides; a-syn alone, a-syn with b-syn 6short, 36, 37, 38, 39, 77, 78. 6 short, 37 and 38;
bar=500 nM. Rest of the peptides bar = 1 mM.
*,P ,0.08.
doi:10.1371/journal.pone.0013863.g002
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screened within the aromatic region (Table 1). b-syn 36 showed
better inhibition than b-syn 39 and dose-dependent inhibition tests
revealed that b-syn 36 is still efficient at an excess of 10:1 (b-syn 36:
a-syn) molar ratio but is less efficient at of 5:1 ratio (Figure 2C).
TEM analysis of a-syn aggregation
Transmission electron microscopy (TEM) analysis was per-
formed on samples of a-syn incubated with and without the b-syn
inhibitor peptides. The samples were taken from the ThT
experiment (presented in Figure 2A). The t-test showed P,0.08.
While the fibrils formed by a-syn alone were large, broad and
had a ribbon-like shape (Figure 2D), only short or no fibrils were
detected in the presence of the b-syn peptides. b-syn 36 almost
completely inhibited fibril formation (Figure 2F). These results are
highly correlated with the results of the ThT assay.
Screening for inhibition of a-syn oligomer formation
To examine the ability of the peptides to inhibit the early stage
of a-syn aggregation, soluble fractions of a-syn were collected after
incubation with and without the b-syn peptides. The reaction
mixtures were separated by SDS-PAGE followed by western blot
analysis using a specific anti a-syn antibody (Santa-Cruz). A
preliminary test of a-syn oligomer formation over time in the
absence of b-syn-derived peptides revealed that high oligomers
could be detected after ,20 hours of incubation (Figure 3A).
Therefore samples incubated with b-syn-derived peptides were
collected after this period of time. Given the current debate
regarding the identity of the toxic species in the process of a-syn
aggregation, it was interesting to note that some b-syn-derived
peptides affected the formation of a-syn fibrils while others
affected the formation of oligomers (Figure 3B). The b-syn 6short
peptide (our positive control peptide) and the b-syn 37 peptide
inhibited formation of mature fibrils but not oligomers, while the
b-syn 78 peptide inhibited oligomers but not fibril formation. The
b-syn 36 peptide inhibited almost completely the formation of
both aggregation types (Figure 2F, 3B).
Modified versions of b-syn 36 peptide inhibit the
aggregation of a-syn and have increased serum stability
For using the b-syn 36 peptide as potential drug it is desirable to
increase its half-life in the patient’s serum, by reducing its
degradation by tissue and serum proteases and peptidases. b-syn
36 is a decamer peptide comprising natural L-amino acids hence is
susceptible to proteolytic degradation. Three modified, more
stable versions of b-syn 36 peptide were designed: the first
composed of D instead of L-amino acids, termed b-syn 36D; the
second was an analogue with retro-inversion of the amino acids
sequence, composed of D-amino acids assembled in the reverse
order from that of the parent L-sequence, termed retro-inverso b-
syn 36. To negate the terminal negative and positive charges of the
retro-inverso peptide, a third modified N-terminal acetylated and
C-terminal amidated peptide was synthesized, termed acetylated
and amidated retro-inverso b-syn 36. The modifications of these
peptides were suspected to alter the efficacy of the lead peptide
without harming its biological activity. Indeed, when tested for
their ability to inhibit a-syn fibril formation, using the ThT
binding assay with a molar ratio of 1:20 or 1:10 in favor of the
peptides, all three modified versions demonstrated a similar
biological effect as b-syn 36 (Figure 4). The t-test showed P,0.08.
Figure 3. (A) Aggregation of a-syn over time. Soluble oligomers were formed while shaking at 37uC. Detection was carried using
western blot analysis. (B) Inhibition of oligomer assembly using b-syn peptides following 24 hours of incubation.
doi:10.1371/journal.pone.0013863.g003
Figure 4. Inhibition of a-syn fibrillar assemblies using ThT
fluorescence assay. Three modified peptides of b-syn 36 were
screened for their inhibition on a-syn aggregation: a-syn alone (black),
b-syn 36 with a-syn (grey), and the modified peptides with a-syn: b-syn
36D (white), retro-inverso b-syn 36 (cross-hatch), acetylated and
amidated retro inverso b-syn 36 (dots). The molar ratios of a-
syn:peptide were 1:20 and 1:10. *, P,0.08.
doi:10.1371/journal.pone.0013863.g004
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the modified retro-inverso peptide was compared by incubating
them for two hours in mouse brain homogenate to model serum
degradation. The results showed that the modified peptide is more
stable than the unmodified b-syn 36 (Figure 5).
To evaluate the binding of the peptides to a-syn, increasing
amounts of a-syn monomers were titrated into a solution of the
modified b-syn 36 peptide and anisotropy was determined (Figure
S1). The affinity constant was determined to be ,1 mM.
NMR analysis of the interaction of b-syn peptides with
a-syn
Studying interactions between a-syn and b-syn by NMR is
severely limited by signal overlap due to the similarity in
their sequences. This was overcome by using the all-D
chirality retro-inverso b-syn 36 peptide (retro-inverso b-syn 36:
R45T44K43S42G41V40Y39L38V37G36), which gives a resolved
spectrum that is distinct from that of a-syn. The residues that
participate in the intermolecular interactions of the retro-inverso
b-syn 36 with a-syn were determined by following changes in their
amide and Ha chemical shifts upon binding. The spectrum of the
peptide in the absence and in the presence of a-syn was
determined under several sets of conditions: Molar ratios of 1:1
and 1:5 peptide to a-syn; peptide concentrations of 160 and
400 mM; temperatures of 4uC, 10uC, 20uC, 25uC, and 37uC; and
using Y39W b-syn 36D analog.
All residues of the retro-inverso b-syn 36 peptide were identified
and assigned (Figure S2). R45 and T44 were not detected in the
amide region, but were identified in the aliphatic region. In all
samples some of the N-terminal region amide signals were lost
between G41 and R45; however, all samples showed the general
trend found for the sample of retro-inverso b-syn 36 with a-syn at
a 1:1 molar ratio, 160 mM, 4uC, at pH 6.7 (Figure 6A and B-E
and Table 1). The amide resonances showed stronger HN and Ha
deviations in residues K43,V 40,L 38 and G36. The participation of
L38 and G36 in binding was ascertained using an additional
truncated peptide, b-syn 36D short, which lacks the first three
amino acids, G36,V 37 and L38, and showed no inhibition of a-syn
aggregation in ThT assay (Figure 6F). These results suggest that
K43,V 40,L 38 and G36 participate in the binding interaction and
that the large chemical shift deviation of L38 and G36 is not only
due to their position at the peptide terminus.
Internalization of b-syn-derived peptides into
mammalian cells
To evaluate the efficacy of the b-syn-derived peptide in
mammalian cell culture, which serves as a model for PD, SH-
SY5Y5 cells over-expressing wild type a-syn were used. They were
first subjected to retinoic acid treatment to induce cell differen-
tiation [41]. After eight days of treatment, cells were cultured into
fresh growing media for 0.5–4 hours followed by incubation with
FITC-conjugated retro-inverso b-syn 36 peptide (green fluores-
cence). After incubation, cells were washed, fixed, and permea-
bilized. Overexpression of wild type a-syn in these cells was
verified using cy5-conjugated goat anti-rabbit antibody (purple
fluorescence) and the cell membrane was marked using Phalloidin
reagent (red fluorescence) (Figure 7). The two concentrations of b-
syn-derived peptide, 50 mM and 250 mM, showed similar results.
After 30 minutes of incubation the peptide did not enter into the
cells. No attachment to the cells was noted. After two hours of
incubation the peptide was detected mostly on the cell surface.
Small amount was detected inside the cells at the concentration of
250 mM. After four hours of incubation, the peptide was clearly
visible inside the cells (Figure 7).
The effect of the retro-inverso b-syn 36 peptide in vivo
The effect of the retro-inverso b-syn 36 peptide on a-syn
aggregation in the living organism was assessed using a Drosophila
model of PD. These transgenic flies over- express the mutated
A53P a-syn in their nervous system, via the Gal4-UAS system. A
common behavioral phenotype of these flies is age-dependent
defective locomotion: While normal flies tend to climb up the side
of the rearing tube, A53T a-syn-expressing flies remain at the
bottom [42]. Crossing male flies carrying the pan-neuronal elav-
Gal4 driver (on their X chromosome) to females carrying the
UAS-regulated A53T a-syn transgene resulted in female offspring
expressing A53T a-syn in their nervous system. This cross was
performed either on regular Drosophila medium or on medium
supplemented with 0.75 mg/mL of the retro-inverso b-syn 36
peptide. The climbing ability of the flies was monitored for 27 days
(Figure 8). Locomotion of flies expressing A53T a-syn in their
Figure 5. Serum stability of b-syn 36 peptides. Brain extract of
wild type ICR white mouse was incubated with the peptides b-syn 36
and retro-inverso b-syn 36 for two hours and loaded on a C18 column
for serum stability analysis. (A) Spectra of the b-syn 36 peptide (blue)
and b-syn 36 peptide with brain extract (red). (B) Spectra of the retro-
inverso b-syn 36 peptide (blue) and retro-inverso b-syn 36 peptide with
brain extract (red). (C) Quantification of the area under the peak. The
area of the peptide in time ‘0’ was determined as 100%. The left
columns represent the peptide (black) and the right columns represent
the peptide with the brain extract (grey).
doi:10.1371/journal.pone.0013863.g005
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The untreated flies became almost immobile by day 27, while the
control classes were very active at this time. In contrast, the treated
flies displayed dramatic improvement, behaving almost identical to
the control classes, presenting an increase of nearly 86% in their
climbing ability in comparison with the untreated group. The
peptide had no significant effect on locomotion of the control flies.
These results indicate significant phenotypic recovery of the A53T
a-syn flies by the retro-inverso b-syn 36 peptide. One tail ANOVA
statistics showed P,0.05.
To evaluate the effect of the retro-inverso b-syn 36 peptide on
a-syn accumulation in the brains of these flies, adult flies were fed
or unfed with the peptide, and their brains were immunostained
with anti a-syn antibody. While a massive accumulation of a-syn
aggregates was detected in the brains of the untreated flies
(Figure 9A), the brains of the treated flies exhibited a greatly
reduced a-syn staining (Figure 9B). Quantification of 8 treated
brains and 7 untreated brains was performed and t-test analysis
showed **, P,0.0001 (Figure 9C).
Discussion
The pathological hallmark of PD is the occurrence of insoluble
intracellular inclusions termed LB and LN within the surviving
dopaminergic neurons of the substantia nigra and several other brain
regions, with a-syn as the major component of these inclusions
[21]. The first indication that a-syn could be involved in
neurodegenerative diseases came from work on the NAC region
isolated from brain amyloid preparations of AD patients [43]. Two
different point mutations, resulting in amino acid substitutions
Figure 6. NMR analysis. (A) Chemical shift deviations of HN (black) and Ha (grey) backbone atoms of the b-syn 36 retro-inverso peptide upon
binding a-syn. (B) Ha-HN region of TOCSY spectra overlay of the b-syn 36 retro-inverso peptide (red) and a-syn (blue) upon binding (green), (C–E)
Expansions of all the retro-inverso peaks that showed deviations upon binding. (F) ThT analysis of fibril formation by a-syn with and without b-syn
36D and its truncated version which lacks amino acids G36,V 37 and L38.
doi:10.1371/journal.pone.0013863.g006
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importance of a-syn when they were indentified as a cause of
rare, inherited forms of PD [19]. Although the etiology of
idiopathic PD is unknown, it is likely to be multifactorial. A
presumptive feature leading to PD is the aggregation of a-syn,
which can be triggered by a range of factors, both environmental
and endogenous [31]. Uversky et al. suggested that the cellular
levels of b-syn and c-syn could constitute such an endogenous
factor [31].
Due to the importance of a-syn aggregation in the pathology of
PD, a useful strategy in drug development is to design short
peptides, or small molecules, that can block, slow down, or reverse
a-syn aggregation, particularly at its early stages [27]. The fact
that a-syn is a natively unfolded protein, makes the rational design
of compounds that can stabilize the native, nontoxic conformation
of a-syn a challenging task [27].
A recently proposed approach is to use the properties of the b-
syn protein as a natural inhibitor of the aggregation of a-syn [32].
In the present work we applied this approach and for the first
time systematically mapped the entire sequence of b-syn to
identify all the domains that have the potential to mediate
molecular recognition events between b-syn and a-syn. Using the
peptide array technique several interaction modules were
identified and some of them were verified by a second round
under more stringent interaction conditions. Decamer peptides
corresponding to the interaction regions were synthesized and
their ability to inhibit the aggregation of a-syn was tested using
ThT and TEM assays. Both methods showed consistent results,
indicating an inhibitory effect of the peptides on fibril formation
by a-syn.
Recent studies reveal that early ‘‘soluble oligomers’’ rather than
mature amyloid fibrils are likely the pathogenic species that drive
neurodegeneration and neuronal cell death [44,45]. It is believed
that the conversion of a-syn into these oligomers, and then into
insoluble fibrils, is initiated by conformational changes from
random coil to b-sheet structure [4,27,46,47]. This suggests that a
candidate anti-amyloid compound should block the very early
stages of amyloid oligomerization. Consequently, we tested the
ability of the interacting b-syn-derived peptides to inhibit the
formation of the soluble fraction of a-syn, and found several
Figure 7. Internalization of retro-inverso b-syn 36 into the cells. Differentiated SH-SY5Y cells over expressing wild type a-syn were incubated
with 50 mM and 250 mM of FITC-conjugated retro-inverso b-syn 36 peptide for periods of half an hour, two hours and four hours. After fixation, the
presence of the FITC-conjugated peptide (green) was monitored inside the cells. Cellular a-syn was detected using cy5-conjugated antibody (purple)
and the cell membrane was marked with Phalloidin (red). (A) After 30 minutes at 37uC there was no peptide staining (green). (B–C) After two hours of
incubation, no or little amount of peptide was detected inside the cells (green). (D–E) After 4 hours of incubation, the peptide was clearly detected
inside the cells. Peptide localization was visualized using an LSM-510 Zeiss confocal microscope.
doi:10.1371/journal.pone.0013863.g007
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appeared to inhibit only the formation of the insoluble fibrils.
While several peptides such as b-syn 6short and b-syn 37 inhibit
fibril formation but not oligomer formation, b-syn 78 inhibits
oligomer formation but not fibril formation. These results support
the latest theory of a two-pathway mechanism of amyloids
aggregation. A similar hypothesis was demonstrated on b-amyloid
in AD [48].
Our best inhibitor candidate was the b-syn 36 peptide which
inhibited both the soluble and insoluble fibrillar aggregates of a-
syn. In addition to its inhibitory properties, this peptide showed no
toxicity towards cultured cells (PC12) when added, at concentra-
tions up to 1 mM, to the their growing medium and incubated for
twenty four hours (data not shown).
The sequence of the b-syn 36 peptide has two interesting
features. First, it contains part of the repetitive domain of
KTKEGV (with a substitution of K for R), which has been
suggested to represent an evolutionary balance between the
functional conformer of a-syn (a-helix and/or random coil) and its
pathogenic b-sheet conformation [49]. Second, the b-syn 36
peptide contains the aromatic amino acid tyrosine, which
according to the ‘‘aromatic stacking’’ hypothesis previously
suggested by us [6], may contribute to the binding energetics as
well as induce order and directionality to the self-assembly of
amyloid structures. These two characteristics may play a role in
the inhibitory potential of this peptide.
Figure 8. Effect of b-syn-derived peptide on locomotive
behavior of PD model flies. Four classes of flies, each containing
five tubes of ten flies were analyzed using the climbing assay: Flies
expressing a-syn A53T grown on a regular medium (black); flies
expressing a-syn A53T grown on medium containing 0.75 mg/mL b-syn
retro inverso peptide (grey); Control flies, not expressing a-syn A53T,
grown on a regular medium (cross-hatch); Control flies, not expressing
a-syn A53T, grown on medium containing 0.75 mg/mL b-syn retro
inverso peptide (white). Results show the percent of flies which climbed
along the test tube after 20 seconds.
*,P ,0.05.
doi:10.1371/journal.pone.0013863.g008
Figure 9. Immunostaining of PD model flies brains. Brains of fourteen-day flies were extracted and immunostained with anti a-syn
antibody followed by a Cy5-conjugated antibody. a-syn is detected in green. (A) Staining of untreated flies expressing a-syn A53T grown on a
regular medium. (B) Staining of flies expressing a-syn A53T treated with b-syn retro inverso peptide. (C) Quantification of treated and untreated
brains. The t-test analysis showed **, P,0.0001.
doi:10.1371/journal.pone.0013863.g009
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are their high sensitivity to proteolytic degradation and lack of
permeation into the cells [50]. We attempted to overcome the first
obstacle by using modified peptides containing D amino acids and
by reversing the peptide sequence. Both modifications retained the
inhibitory effect of the peptides. In addition to its excellent
inhibition ability, the retro-inverso b-syn 36 modified peptide
displayed increased stability towards proteolytic degradation.
Concerning the cell permeability, we showed that the stable
retro-inverso b-syn 36 peptide can penetrate differentiated
SHSY5Y cells without adding any internalization motif.
In this context, it is worth mentioning that although a-syn is a
typical cytoplasmic protein, a small amount of both monomeric
and aggregated forms were reported to be secreted from cells and
exist in human body fluids, such as cerebrospinal fluid [51,52].
Furthermore, extracellular a-syn was shown to be capable of
entering cells, and the mechanism of its internalization was
suggested to depend on the assembly state of the protein:
aggregated forms of a-syn, both fibrils and oligomers, enter into
cells via receptor-mediated endocytosis, while monomeric a-syn
diffuses passively across the plasma membrane [53]. It is worth
noting that there is high homology between a-syn and b-syn,
especially in the N terminal region, and the sequence of the b-syn
36 peptide can be detected within the sequence of a-syn at the
same position with one amino acid substitution of lysine to
arginine. We therefore speculate that the identified peptide either
diffuses passively across the plasma membrane or enters into cells
via the same receptor-mediated endocytosis as a-syn. In
accordance with the in vitro results, the retro-inverso b-syn 36
modified peptide alleviated a-syn engendered symptoms in a
transgenic fly model of PD and significantly reduced the
accumulation of aggregated a-syn in their brains. Despite its
specificity to a-syn, it will be interesting to examine the efficacy of
the peptide in other fly models of amyloidogenic proteins such as
polyQ and b-amyloid.
The backbone chemical shift deviations of the retro-inverso b-
syn 36 peptide upon binding to a-syn, as determined by NMR, are
largest for the hydrophobic residues L38 and V40, in addition to the
more flexible terminal residues K43 and G36. Residues L38 and V40
surround the aromatic Y39, previously shown to participate in the
oligomeric interaction [5,6], although Y39 itself showed little
change in chemical shift upon binding a-syn. It is possible that the
bulky side chain of Y39 stabilized a local conformation in the
unbound structure, which was not significantly changed upon
interacting with a-syn. The two neighboring hydrophobic
residues, L38 and V40, may reside within a hydrophobic binding
interface with a-syn. The chemical environment of this region,
reflected in the deviations in chemical shift, changes from a
monomeric, exposed conformation to a more shielded, hydropho-
bic environment upon interacting with a-syn.
Taken together, our results support the idea of using the
naturally occurring b-syn protein for the development of inhibitors
of a-syn aggregation. We have mapped a decamer peptide in b-
syn which is able to inhibit both the early and late stages of a-syn
aggregation and we were able to stabilize it using several
modifications. The modified decamer peptide showed a significant
amelioration of PD-associated defects in a transgenic fly model.
Supporting Information
Figure S1 The affinity of the modified b-syn 36 containing
tryptophan instead of tyrosine towardsa-syn monomers was
examined using fluorescent anisotropy. Kd = 1 mM.
Found at: doi:10.1371/journal.pone.0013863.s001 (0.02 MB
TIF)
Figure S2 NMR assignment spectra of b-syn 36 retro-inverso
peptide. Overlay of HN-Ha interaction regions of TOCSY (red)
and NOESY (green) spectra of taken under identical conditions
according to which assignment was performed.
Found at: doi:10.1371/journal.pone.0013863.s002 (8.35 MB
TIF)
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